MADELEINE DUVIC, M.D.
Dermatology at Travis St, Houston, TX

4804651, Feb 14, 1989

Jun 9, 1987

7/059907

Madeleine Duvic - Houston TX
Gary W. Brewton - Houston TX

Board of Regents, The University of Texas System - Austin TX

A61K 3170

514 50

Disclosed are methods and compositions employing azidothymidine for the treatment of psoriasis. Oral, parenteral or topical dosage forms are administered to affected individuals in therapeutically effective amounts. Typically, between about 100 and about 4000 mg of azidothymidine is administered orally per day until symptoms of the disease such as inflammation, irritation, or incidence or size of lesions, are abated. Also disclosed are topical dosage forms, including pharmaceutically acceptable creams, lotions, ointments, salves and the like, which include therapeutically effective concentrations of azidothymidine. Such topical compositions may further include effective amounts of a corticosteroid or a cutaneous surface acting antipsoriatic agent, such as a keratolytic agent.

5691460, Nov 25, 1997

Jul 22, 1994

8/279270

Madeleine Duvic - Houston TX
Wanda T. Schroeder - Houston TX

The University of Texas System - Austin TX

C07H 2102, C07H 2104

536 232

The present invention relates to the cloning, sequencing and characterization of a unique human epidermal surface antigen, ESA, and to methods for preparing and using the ESA gene and protein. The ESA gene is mapped to the region 17q11-12, on the long arm of chromosome 17, in the same area as the NF1 locus (the gene for von Recklinghausen neurofibromatosis). The mouse ESA has been located to chromosome 11. ESA mRNA is expressed in cultured keratinocytes and melanocytes, as well as in several carcinoma cell lines. Methods employing the antigen and/or DNA segments in diagnostic and therapeutic methods, including gene therapy, for the treatment of a variety of diseases, including cancer and autoimmunity, are disclosed. Methods for targeting molecules to the suprabasal epidermal cell layer are also presented.